Clinical trials: Placebo Response
Primary Fibromyalgia
Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia
The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacokinetics of milnacipran in pediatric patients aged 13 to 17 years with primary fibromyalgia.
- Trial name
- MyFi (NCT01328002)
- Testing
- Milnacipran
- Where
- 47 sites in United States
- Volunteers
- 116 people
- Sponsor
- Forest Laboratories
Rheumatoid Arthritis
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)
This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF-alpha therapy.
- Trial name
- SCRIPT (NCT00476996)
- Testing
- Leflunomide, Methotrexate, Ocrelizumab
- Where
- 266 sites in United States, Argentina and 23 more
- Volunteers
- 836 people
- Sponsor
- Genentech, Inc.
Asthma
A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise
This study is intended to determine the dose response and duration of action of GSK2190915 in mild asthmatic adult subjects who experience exercise-induced bronchoconstriction.
- Trial name
- NCT00812929
- Testing
- GSK2190915
- Where
- 6 sites in United States
- Volunteers
- 47 people
- Sponsor
- GlaxoSmithKline
Diffuse Large B-cell Lymphoma
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients had achieved complete response with first-line rituximab-chemotherapy
- Trial name
- PILLAR2 (NCT00790036)
- Testing
- Everolimus
- Where
- 202 sites in United States, Argentina and 32 more
- Volunteers
- 742 people
- Sponsor
- Novartis Pharmaceuticals
Crohn's Disease
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
This study in patients with moderately to severely active Crohn's disease is designed to establish the efficacy and safety of vedolizumab for the induction of clinical response and remission.
- Trial name
- GEMINI III (NCT01224171)
- Testing
- vedolizumab
- Where
- 41 sites in United States, Canada
- Volunteers
- 416 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Allergic Rhinitis
A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis
The purpose of this study is to assess the safety and tolerability of different doses of PF-06444753 and PF-06444752 in subjects with allergic rhinitis.
- Trial name
- NCT01723254
- Testing
- IGE-1, IGE-2, Saline
- Where
- 4 sites in Canada
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cholestasis
Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis
This study is being conducted to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus (itch) in participants with primary biliary cholangitis (PBC).
- Trial name
- NCT02966834
- Testing
- GSK2330672
- Where
- 66 sites in United States, Australia and 8 more
- Volunteers
- 147 people
- Sponsor
- GlaxoSmithKline
Pelvic Pain Associated With Refractory Endometriosis
A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis
The purpose of this study is to determine efficacy, safety, tolerability and pharmacokinetics of multiple doses of BGS649 with concurrent daily administration of combined oral contraception in patients with refractory…
- Trial name
- NCT01116440
- Testing
- BGS649
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 27 people
- Sponsor
- Mereo BioPharma
Moderate to Severe Plaque-type Psoriasis
First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks
The purpose of this study is to demonstrate efficacy of secukinumab at Week 12 based on PASI and IGA response rates versus placebo in subjects with moderate to severe chronic plaque-type psoriasis.
- Trial name
- FEATURE (NCT01555125)
- Testing
- secukinumab 150 mg, secukinumab 300 mg
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Crohn's Disease
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response and remission at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission…
- Trial name
- GEMINI II (NCT00783692)
- Testing
- vedolizumab
- Where
- 114 sites in United States, Canada and 1 more
- Volunteers
- 1,116 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Hypercholesterolemia
A Study to Evaluate the Effects of Ezetimibe (MK-0653) on the Postprandial (Following a Meal) Lipoprotein Response in Participants With Primary Hypercholesterolemia (High Cholesterol) (MK-0653-072)(COMPLETED)
A study to evaluate the cholesterol-lowering effects of ezetimibe in participants with primary hypercholesterolemia (high cholesterol) after eating a meal that is high in cholesterol.
- Trial name
- NCT00101439
- Testing
- ezetimibe
- Volunteers
- 58 people
- Sponsor
- Organon and Co
COVID-19 Vaccination
RCT of Mushroom Based Natural Product to Enhance Immune Response to COVID-19 Vaccination
This is a randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of two polypore mushrooms, Fomitopsis officinalis and Trametes versicolor (FoTv), for use as an adjunct to vaccination for COVID-19 in a…
- Trial name
- MACH19 (NCT04951336)
- Testing
- FoTv
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Major Depressive Disorder
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01436149
- Testing
- SPD489 (Lisdexamfetamine dimesylate )
- Where
- 85 sites in United States, Canada and 4 more
- Volunteers
- 1,262 people
- Sponsor
- Shire
Cervical High Grade Squamous Intraepithelial Lesion
Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL
Cervical cancer occurs commonly in HIV-infected women in South Africa. These women have poor response to treatment of cervical cancer precursors.
- Trial name
- NCT01928225
- Testing
- Human Papillomavirus vaccine
- Volunteers
- 180 people
- Sponsor
- University of Witwatersrand, South Africa
RSV Immunisation, Healthy Volunteers
A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers
This study was a Phase III, parallel group, randomized, observer blind, placebo controlled, multi-national, multi-center, multi-arm study conducted in 42 healthy children enrolled at 6 months to <22 months of age.
- Trial name
- OPAL (NCT06705140)
- Testing
- Low Dose (LD) RSVt vaccine, Standard Dose (SD) RSVt vaccine, High Dose (HD) RSVt vaccine
- Where
- 3 sites in Honduras
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Major Depressive Disorder
Neurobiological Bases of Placebo Response in Major Depressive Disorder
We are doing this research study to find out if people who get better while taking a specific kind of antidepressant medication (a selective serotonin reuptake inhibitor, or SSRI) and people who get better while taking placebo…
- Trial name
- NCT01787240
- Testing
- Escitalopram 10mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone
The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to…
- Trial name
- NCT03738215
- Testing
- Cariprazine
- Where
- 125 sites in United States, Bulgaria and 5 more
- Volunteers
- 759 people
- Sponsor
- AbbVie
Crohn's Disease
Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease
This is a multi-centre, randomized, double-blind, dose response clinical study of CDP870 in patients with Crohn's disease.
- Trial name
- NCT00291668
- Testing
- Certolizumab Pegol
- Where
- 22 sites in Japan
- Volunteers
- 94 people
- Sponsor
- UCB Pharma
Asthma
Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects
This is a randomized, placebo-controlled, 2-period crossover, escalating repeat dose study, aiming to investigate whether higher potency of different inhaled corticosteroid confers an improvement in the topical efficacy to…
- Trial name
- NCT02991859
- Testing
- Fluticasone furoate (FF) Dry Powder Inhaler, Fluticasone propionate (FP) Dry Powder Inhaler, Budesonide (BUD) Turbuhaler
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 56 people
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above
The aim of this study is to demonstrate the non-inferiority (NI) of the immune response and evaluate safety of RSVPreF3 older adults (OA) investigational vaccine in adults 50-59 years of age (YOA), including those who are at…
- Trial name
- NCT05590403
- Testing
- RSVPreF3 OA investigational vaccine
- Volunteers
- 1,544 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline